[{"id":"16167a12-edc3-4776-9942-2975c9714e30","acronym":"","url":"https://clinicaltrials.gov/study/NCT03258593","created_at":"2025-06-07T14:49:21.304Z","updated_at":"2025-06-07T14:49:21.304Z","phase":"Phase 1","brief_title":"Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)","source_id_and_acronym":"NCT03258593","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Vicineum (oportuzumab monatox)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 06/07/2018","start_date":" 06/07/2018","primary_txt":" Primary completion: 08/01/2022","primary_completion_date":" 08/01/2022","study_txt":" Completion: 10/17/2022","study_completion_date":" 10/17/2022","last_update_posted":"2025-05-30"}]